Compare Heron Therapeutics Inc (HRTX) vs PPG Industries, Inc. (PPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs PPG Industries, Inc. — how do they compare? Heron Therapeutics Inc trades at $0.4 (market cap $68.01M), while PPG Industries, Inc. trades at $104.27 (market cap $23.44B). The key difference: PPG Industries, Inc. is far larger — about 344.7× Heron Therapeutics Inc's market cap, and PPG Industries, Inc. pays a 2.81% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and PPG Industries, Inc. for 68 Days on average.
| HRTX | PPG | |
|---|---|---|
Market Cap | $68.01M | $23.44B |
Volume | 1,891,941 | 2,064,777 |
Sector | Health | Basic Materials |
52-Week High | $1.49 | $131.56 |
52-Week Low | $0.27 | $94.34 |
Typical Hold Time | 35 Days | 68 Days |
Enterprise Value | $174.75M | $29.31B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3967, up 1.72% today, with a bullish technical signal from moving averages but mixed earnings. The company reported a net loss of $20.20 million in 2025, with revenue of $154.90 million, and has a high gross margin of 70.07% but negative profitability metrics. Recent Q2 2026 results missed EPS estimates, though Q4 2025 beat expectations. Analyst consensus is strongly bullish with 17 buy ratings.
The outlook is cautious due to persistent losses and cash burn, but strong analyst support and a low P/S ratio of 0.44 may appeal to value investors. Key risks include ongoing unprofitability and competitive pressures in the biotech sector. Investors should weigh the high institutional optimism against fundamental challenges.
PPG Industries trades at $104.79, down 0.28% for the day, with a bearish technical signal from moving averages and neutral oscillators. The company reported 2025 revenue of $15.88 billion and net income of $1.58 billion, with a P/E ratio of 15.13. Recent earnings showed mixed results, missing in Q4 2025 and Q2 2026 but beating in Q1 2026. Analyst consensus is a Buy with a $130 price target, while recent news highlights margin pressures in the Automotive Refinish segment.
The outlook for PPG is cautiously optimistic, supported by strong profitability metrics like a 9.57% net income margin and 19.63% ROE, but risks include segment-specific weaknesses and macroeconomic headwinds. Upside potential exists if the company meets Q3 2026 earnings expectations and sustains cost-control measures, though investors should monitor auto refinish performance and global demand trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →
